Keyphrases
Methicillin-resistant Staphylococcus Aureus
100%
COVID-19
53%
Streptococcus Pneumoniae
50%
Vancomycin
42%
Mouse Model
42%
Airway Epithelial Cells
40%
Mucin 5AC (MUC5AC)
40%
Fusobacterium nucleatum (F. nucleatum)
39%
S. Pneumoniae
36%
Japan
36%
Pneumonia
35%
Pseudomonas Aeruginosa (P. aeruginosa)
34%
Murine Model
33%
Staphylococcus Aureus Bacteremia
33%
Prevotella Intermedia
31%
In Vivo Efficacy
29%
Daptomycin
29%
Azithromycin
29%
Supernatant
28%
Levofloxacin
27%
Lung
27%
Ventilator-associated Pneumonia
26%
Type I Interferon
26%
Lung Abscess
26%
Complete Genome Sequence
26%
Fusobacterium Necrophorum
26%
Mice Pneumonia Model
26%
Respiratory Failure
26%
Linezolid
26%
Quantitative PCR
25%
Ground-glass Opacity
25%
Neutralizing Activity
25%
Bacteremia
24%
CA-MRSA
22%
Interleukin-6
21%
Fluoroquinolones
21%
Pathogenicity
20%
Neutralizing Antibodies
20%
Liver Abscess
20%
SARS-CoV-2 Infection
19%
Inflammatory Cytokines
19%
Omicron Variant
18%
Quinolones
18%
Pulmonary Abscess
17%
Respiratory Infection
17%
Titer
17%
Macrolides
17%
Bacterial Load
17%
Methicillin-resistant Staphylococcus Aureus Pneumonia
17%
Periodontal Bacteria
16%
Pharmacology, Toxicology and Pharmaceutical Science
Methicillin-Resistant Staphylococcus Aureus
79%
Infection
71%
Methicillin Resistant Staphylococcus Aureus Infection
47%
Vancomycin
42%
Pseudomonas aeruginosa
40%
Mucin 5AC
40%
Bloodstream Infection
36%
SARS Coronavirus
33%
Lung Abscess
33%
Fusobacterium nucleatum
30%
Daptomycin
29%
Mouse Model
29%
Levofloxacin
28%
Quinolone Derivative
28%
Macrolide
28%
Prevotella intermedia
26%
Linezolid
26%
Interferon Type I
26%
Respiratory Failure
26%
Interleukin 6
23%
Respiratory Tract Infection
22%
Infectious Agent
18%
Azithromycin
17%
Mucin
17%
Streptococcus
16%
Quinolone
16%
Sitafloxacin
15%
Interferon
15%
Bacterial Infection
14%
Hemolysin
14%
Cohort Study
14%
Cytokine
13%
Minimum Inhibitory Concentration
13%
Cystic Fibrosis
13%
Actinomyces
13%
Streptococcus Agalactiae
13%
Pazufloxacin
13%
Moxifloxacin
13%
Penicillinase
13%
Lung Infection
13%
Garenoxacin
13%
Neutralizing Antibody
13%
Antiinfective Agent
13%
Ciprofloxacin
13%
Mycoplasma Pneumonia
13%
Hospital Mortality
13%
Thrombocyte Activating Factor Receptor
13%
Teicoplanin
13%
Ventilator Associated Pneumonia
13%
Biapenem
13%
Immunology and Microbiology
Methicillin-Resistant Staphylococcus Aureus
87%
Pneumococcus
46%
Severe Acute Respiratory Syndrome Coronavirus 2
46%
Abscess
43%
MUC5AC
40%
COVID-19
34%
Immunology
34%
Fusobacterium nucleatum
30%
Omicron Coronavirus Variant
29%
interferon
28%
Interleukin 6
26%
Pathogenicity
26%
Neutralizing Antibody
26%
Prevotella intermedia
26%
Streptococcus Pneumonia
26%
Minimum Inhibitory Concentration
26%
Fusobacterium necrophorum
26%
Mouse Model
26%
Wild Type
25%
Supernatant
24%
Infectious Agent
21%
Antibody Response
20%
Titer
19%
Bronchoalveolar Lavage Fluid
19%
Cytokine
17%
Mucin
15%
Gene Expression
15%
Severe Asthma
14%
Hemolysin
14%
Proinflammatory Cytokine
14%
Bacterial Load
13%
Breakthrough Infection
13%
Booster Dose
13%
Pseudomonas aeruginosa
13%
Hospital Mortality
13%
Airflow
13%
Empyema
13%
Acinetobacter Baumannii
13%
Brucella
13%
Vein
13%
Agar
13%
Thrombocyte Activating Factor
13%
Relapsing Polychondritis
13%
Cell Population
13%
Legionella pneumophila
13%
Adalimumab
13%
Pulmonary Inflammation
13%
Serotype
13%
Receptor Binding
12%
Staphylococcus Aureus
11%